Cargando…
Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells
BACKGROUND: Drug resistance is a major problem in the treatment of leukemia with doxorubicin (Dox), and the erythroblastosis virus E26 oncogene homolog 1 (ETS1) gene is associated with drug resistance. Olmutinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor...
Autores principales: | Zhong, Jiansheng, Zhang, Jinli, Yu, Xiaoyang, Zhang, Xing, Dian, Linping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466836/ https://www.ncbi.nlm.nih.gov/pubmed/32830792 http://dx.doi.org/10.12659/MSM.924922 |
Ejemplares similares
-
Downregulation of miR-222-3p Reverses Doxorubicin-Resistance in LoVo Cells Through Upregulating Forkhead Box Protein P2 (FOXP2) Protein
por: Wang, Huaiming, et al.
Publicado: (2019) -
Dehydrocostus Lactone Enhances Chemotherapeutic Potential of Doxorubicin in Lung Cancer by Inducing Cell Death and Limiting Metastasis
por: Sheng, Wei, et al.
Publicado: (2018) -
Doxorubicin-Induced Cancer Cell Senescence Shows a Time Delay Effect and Is Inhibited by Epithelial-Mesenchymal Transition (EMT)
por: Hu, Xuerui, et al.
Publicado: (2019) -
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis
por: Lu, Jia, et al.
Publicado: (2017) -
Sirtuin 1 (Sirt1) Overexpression in BaF3 Cells Contributes to Cell Proliferation Promotion, Apoptosis Resistance and Pro-Inflammatory Cytokine Production
por: Wang, Qian, et al.
Publicado: (2017)